Oric Pharmaceuticals (ORIC) AI Stock Analysis

• Market Cap: $1.03B
• Dividend Yield: N/A
• Average Volume (3M): 1.50M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: 4.29%
• Country: US
• Employees: 122
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 97,389,280
• 10 Day Avg. Volume: 1,659,105
• 30 Day Avg. Volume: 1,495,914
• PEG Ratio: 0.66
• Price to Book (P/B): 2.31
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.94
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -3.04K
• Enterprise Value/Ebitda: -6.62
• 1Y Price Target: $20.10
• Price Target Upside: 89.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 12
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $10.50 ▼(-1.04% Downside)

Overall score is held back primarily by the pre-revenue model with substantial and slightly worsening losses and heavy cash burn, partially offset by a strong, low-debt balance sheet. Technical signals are mixed (near-term strength but negative MACD and intermediate trend pressure), while valuation is constrained by negative earnings and no dividend. Recent positive clinical-trial corporate updates provide a supportive catalyst offset.

Positive Factors

Cash runway

A $244M financing and ~$413M of cash and investments provide multi-year runway into 2H 2028, materially reducing near-term financing risk. This funding enables execution of registrational plans, clinical readouts, and dose-optimization without immediate dilution pressure.

Low financial leverage

Very low debt relative to equity and substantial assets imply minimal leverage and financial flexibility. This balance sheet strength supports sustained R&D spend, strategic partnerships, and optionality to fund trials or license assets without overreliance on borrowed capital.

Differentiated clinical data

Robust systemic and intracranial activity and selection of a Phase 3 dose for enozertinib signal potential best-in-class positioning in EGFR exon 20/PACC NSCLC. Durable clinical differentiation raises likelihood of a viable registrational path and long-term commercial opportunity if confirmed.

Negative Factors

Pre-revenue model

As a pre-revenue biotech, ORIC relies on financing to fund operations while burning substantial cash. Persistent negative free cash flow and large net losses mean the company must convert trials to value or raise capital again, a structural risk to dilution and long-term sustainability.

Worsening profitability trend

Rising net losses year-over-year indicate growing cost intensity and limited operating leverage. If development expenses continue to outpace progress to revenue-generating milestones, equity value could be eroded over time and pressure resources for future program investment.

Concentration of clinical risk

Company value is concentrated in a few late-stage programs; success hinges on upcoming pivotal readouts and trial initiations. Binary outcomes of these trials create durable execution risk: failures would sharply curtail commercialization prospects and leave limited alternative revenue drivers.

Oric Pharmaceuticals Business Overview & Revenue Model

Company Description

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

How the Company Makes Money

Oric Pharmaceuticals generates revenue primarily through the development and commercialization of its drug candidates. The company seeks to monetize its pipeline by advancing its proprietary compounds through clinical trials and obtaining regulatory approval, which then allows it to either market these drugs directly or license them to larger pharmaceutical companies. Key revenue streams include potential milestone payments, royalties from partnerships with larger pharmaceutical companies, and future product sales upon successful drug approval. Oric may also engage in strategic collaborations and partnerships to co-develop or out-license its technologies, which can provide upfront payments and shared development costs, contributing to its revenue.

Oric Pharmaceuticals Financial Statement Overview

Summary

Development-stage profile with $0 revenue and sizable, slightly worsening losses and cash burn (TTM net loss ~-$135.3M; TTM FCF ~-$117.5M). Offsetting strength is a low-debt balance sheet (~$3.3M debt vs. ~$406.9M equity) that supports funding flexibility/runway.

Income Statement

ORIC continues to operate pre-revenue (revenue is $0 in both TTM (Trailing-Twelve-Months) and recent annual periods), and losses remain substantial. Net loss widened in TTM (Trailing-Twelve-Months) (about -$135.3M) versus FY2024 (-$127.8M) and is meaningfully worse than FY2021–FY2023, indicating rising cost intensity and limited near-term operating leverage. While this profile is not unusual for early-stage biotech, the trajectory shows worsening profitability rather than improvement.

Balance Sheet

The balance sheet is a relative strength: debt is very low (TTM total debt ~$3.3M) against a sizable equity base (TTM equity ~$406.9M), implying minimal financial leverage and good flexibility. Total assets increased to ~$431.2M in TTM (Trailing-Twelve-Months) from ~$274.1M in FY2024, supporting liquidity/runway. The key weakness is ongoing negative returns on equity driven by persistent net losses, which will continue to pressure equity over time if losses persist.

Cash Flow

Cash burn remains heavy and consistent with a development-stage biotech model. TTM (Trailing-Twelve-Months) operating cash flow was about -$116.8M and free cash flow about -$117.5M, and free cash flow deteriorated versus FY2024 (negative growth). A positive offset is that cash outflows broadly track reported losses (free cash flow is roughly in line with net loss), suggesting limited earnings-quality distortion—but the absolute burn rate is the main risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-304.00K	-1.11M	-1.03M	0.00	0.00	0.00
EBITDA	-139.47M	-126.74M	-109.75M	-85.80M	-77.97M	-48.37M
Net Income	-135.27M	-127.85M	-100.70M	-89.12M	-78.72M	-73.70M
Balance Sheet
Total Assets	431.19M	274.14M	254.69M	250.36M	298.64M	299.00M
Cash, Cash Equivalents and Short-Term Investments	287.14M	255.96M	208.19M	206.27M	236.98M	293.60M
Total Debt	3.30M	3.18M	10.21M	12.10M	1.93M	0.00
Total Liabilities	24.27M	31.02M	30.60M	28.01M	25.67M	9.22M
Stockholders Equity	406.92M	243.12M	224.09M	222.35M	272.98M	289.78M
Cash Flow
Free Cash Flow	-117.49M	-113.85M	-86.54M	-77.22M	-60.48M	-45.94M
Operating Cash Flow	-116.78M	-112.66M	-85.69M	-75.14M	-59.54M	-45.27M
Investing Cash Flow	-122.36M	22.14M	-43.40M	-109.25M	158.44M	-215.96M
Financing Cash Flow	244.58M	126.55M	85.66M	25.23M	49.13M	250.51M

Oric Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 10.61
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORIC, the sentiment is Neutral. The current price of 10.61 is below the 20-day moving average (MA) of 10.87, above the 50-day MA of 10.12, and above the 200-day MA of 10.02, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 49.74 is Neutral, neither overbought nor oversold. The STOCH value of 30.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ORIC.

Oric Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PRAX	60 Neutral	$8.31B	-23.51	-75.20%	―	364.98%	-25.33%
SYRE	58 Neutral	$2.49B	-14.72	-32.63%	―	―	-123.65%
PHAR	58 Neutral	$1.18B	1,172.22	0.44%	―	26.54%	―
TRVI	57 Neutral	$1.47B	-30.84	-36.87%	―	―	15.84%
ORIC	54 Neutral	$1.03B	-6.13	-39.73%	―	―	4.29%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRME	50 Neutral	$627.27M	-2.36	-112.34%	―	647.13%	26.79%

Oric Pharmaceuticals Corporate Events

Oric Pharmaceuticals Highlights Promising Enozertinib Trial Results

On December 6, 2025, Oric Pharmaceuticals presented an update on its enozertinib (ORIC-114) program, highlighting data from a Phase 1b trial. The update revealed that enozertinib shows promising systemic and intracranial activity in EGFR-mutated NSCLC, potentially establishing a best-in-class profile. With no significant off-target toxicity and a manageable safety profile, enozertinib could address a significant commercial opportunity in the U.S., estimated at $3.0 to $3.5 billion annually, targeting approximately 9,000 patients with NSCLC.

The most recent analyst rating on (ORIC) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.

Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results

Oric Pharmaceuticals announced an update on their ORIC-944 clinical trials, highlighting the drug’s strong clinical activity when combined with apalutamide and darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) who were previously treated with abiraterone. The Phase 1b trial, which involves 20 patients, showed promising PSA response rates, with ongoing dose optimization expected to provide further data in the first quarter of 2026. This development could enhance Oric’s position in the oncology market by potentially offering a new therapeutic option for mCRPC patients.

The most recent analyst rating on (ORIC) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oric Pharmaceuticals stock, see the ORIC Stock Forecast page.